Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Development Projects, Regulatory Filings Increasing Thanks to Innovation Premium: PhRMA, EFPIA
August 27, 2015
- MHLW Seeks 30.7 Trillion Yen in FY2016 Budget, 104.3 Billion for Drug, Healthcare Initiatives
August 27, 2015
- Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
- Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
August 26, 2015
- 4 Pharma Groups Welcome MHLW’s “Comprehensive Strategy”
August 25, 2015
- MHLW OKs New Indications for Remicade, Other Products
August 25, 2015
- MHLW Reveals Outline of “Comprehensive Strategy” for Pharma Sector
August 25, 2015
- Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 10 - August 23
August 24, 2015
- PMDA Reviewing Opdivo for Risk of Myasthenia Gravis
August 24, 2015
- Novartis’s Equa-Metformin Combination Drug Added to PAFSC 1st Committee’s Review List for Aug. 28
August 24, 2015
- MHLW Designates Carfilzomib as Orphan Drug
August 21, 2015
- Lawmakers Discuss Cost-Effectiveness of Measures to Prevent Cervical Cancer
August 21, 2015
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
- Japan, South Korea Sign MOU for Regulatory Affairs
August 21, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- PMDA, AMED Ink Pact to Spur Commercialization of Novel Drugs
August 20, 2015
- PAFSC’s 2nd Committee to Discuss AbbVie’s Combination Drug for Hepatitis C on Aug. 31
August 19, 2015
- PAFSC 2nd Committee to Discuss Orphan Drug Designation for 3 APIs on Aug. 31
August 19, 2015
- 18 Firms Win Approval for Jzoloft Generics, 25 for Exforge Generics
August 18, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…